A Senate deal to cap the cost of insulin at $35 a month for individuals with private insurance and Medicare poses a new test of whether Democrats can make good on campaign pledges to rein in drug costs.
Why it matters: With most of President Biden’s health agenda still stalled in Congress, the plan unveiled on Wednesday could be a politically appealing way to limit out-of-pocket costs for more than 37 million Americans with diabetes.
